~11 spots leftby Apr 2026

Precision Exercise Training for Sepsis

(PRECISE Trial)

GK
Overseen byGraeme Koelwyn, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of British Columbia
Must not be taking: Immunomodulatory drugs
Disqualifiers: Diabetes, Autoimmune diseases, Hypertension, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a personalized exercise program for sepsis survivors to see if it improves their ability to exercise and boosts their immune system. The program includes tailored strength and aerobic exercises over a few months.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on daily immunomodulatory drugs, you cannot participate in the trial.

What data supports the effectiveness of the treatment Precision Exercise Training for Sepsis?

Research suggests that exercise training can protect against organ dysfunction in sepsis, improve physical activity and muscle strength in survivors, and reduce mortality in patients with low muscle mass. Early exercise rehabilitation also helps improve functional recovery in severe sepsis patients.12345

Is Precision Exercise Training generally safe for humans?

Research suggests that exercise training, including aerobic and resistance training, is generally safe for humans. High-intensity strength training may even be safer for the cardiovascular system than low-intensity training, as it causes fewer increases in blood pressure and cardiac output.678910

How is Precision Exercise Training different from other treatments for sepsis?

Precision Exercise Training is unique because it involves individualized exercise plans that combine strength and aerobic exercises, which may help protect against organ damage in sepsis by improving fitness and modulating biological responses, unlike standard treatments that do not typically include exercise.23111213

Research Team

GK

Graeme Koelwyn, PhD

Principal Investigator

University of British Columbia

Eligibility Criteria

This trial is for sepsis survivors over 19 years old with reduced cardiorespiratory fitness, who can commit to a 12-week exercise program. They must have had symptoms like fast breathing, confusion, or low blood pressure. It's not for those on oxygen therapy, recent heart events, uncontrolled conditions like diabetes or hypertension, pregnant women, or those unable to consent.

Inclusion Criteria

Signed informed consent
My heart and lung fitness is below 80% of what's expected for my age and sex.
≥60 days prior to study enrollment, known or suspected infection that includes at least two of the following clinical criteria that together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate >22breaths/min, altered mentation, or systolic blood pressure <100mmHg
See 2 more

Exclusion Criteria

Desaturation during exercise SpO2<85%
Known pregnancy/ intending to get pregnant within 28 days of enrolling in the study or breastfeeding
Cardiovascular contraindication or musculoskeletal limitations to exercise as assessed during the cardiopulmonary exercise test
See 7 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants complete 12-weeks of precision exercise training consisting of individualized, nonlinear periodized strength and aerobic exercise training

12 weeks
36 sessions (in-person)

Attention Control

Participants in the control group receive usual care procedures and general lifestyle advice 1x per week

12 weeks
12 contacts (virtual)

Follow-up

Participants are monitored for changes in clinical biomarkers and health-related quality of life

4 weeks

Treatment Details

Interventions

  • Precision Exercise Training (Behavioural Intervention)
Trial OverviewResearchers are testing if a personalized 12-week exercise program helps improve the ability of sepsis survivors to tolerate physical activity compared to usual care and lifestyle advice. Participants will do strength and aerobic exercises three times weekly and their progress will be measured against an attention control group.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Exercise InterventionExperimental Treatment1 Intervention
Patients will participate in a 12-week (36 sessions) precision exercise training intervention
Group II: Attention ControlActive Control1 Intervention
Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials
1,506
Recruited
2,528,000+
Dr. Christopher Haqq profile image

Dr. Christopher Haqq

University of British Columbia

Chief Medical Officer since 2019

MD, University of British Columbia

Bekki Bracken Brown profile image

Bekki Bracken Brown

University of British Columbia

Chief Executive Officer since 2023

Bachelor's degree from Duke University

St. Paul's Hospital, Canada

Collaborator

Trials
48
Recruited
13,200+

Providence Health & Services

Collaborator

Trials
131
Recruited
827,000+
Dr. Laurel Soot profile image

Dr. Laurel Soot

Providence Health & Services

Chief Medical Officer since 2024

MD, FACS

Erik Wexler profile image

Erik Wexler

Providence Health & Services

Chief Executive Officer

Bachelor's degree in Business Administration from the University of Massachusetts Amherst

Vancouver Coastal Health Research Institute

Collaborator

Trials
30
Recruited
5,600+

Simon Fraser University

Collaborator

Trials
59
Recruited
12,500+

Dr. Joy Johnson

Simon Fraser University

Chief Executive Officer since 2020

PhD in Nursing, University of Alberta

Dr. Dilson Etcheverry Rassier

Simon Fraser University

Chief Medical Officer since 2023

MD from Harvard Medical School

Findings from Research

In a study of 516 sepsis patients admitted to the ICU, those with low skeletal muscle mass who received ICU-rehabilitation had significantly lower in-hospital and 6-month mortality rates compared to those who did not receive rehabilitation (26.0% vs. 39.8% and 38.6% vs. 51.5%, respectively).
ICU-rehabilitation was found to be independently associated with a 34% reduction in 1-year mortality for patients with low skeletal muscle mass, highlighting the importance of early rehabilitation in this vulnerable group.
ICU rehabilitation is associated with reduced long-term mortality from sepsis in patients with low skeletal muscle mass: a case control study.Kim, T., Huh, S., Kim, SY., et al.[2022]
Aerobic exercise training significantly protects against sepsis-associated acute kidney injury (AKI) by enhancing the expression of R-spondin 3 (RSPO3), which helps maintain kidney function and integrity during sepsis.
The study found that exercise or RSPO3 administration reduced inflammation and endothelial damage in the kidneys, while knocking out RSPO3 worsened kidney injury, highlighting its crucial role in protecting against LPS-induced renal complications.
Increased R-spondin 3 contributes to aerobic exercise-induced protection against renal vascular endothelial hyperpermeability and acute kidney injury.Xu, QF., Zhang, H., Zhao, Y., et al.[2023]
Inadequate exercise significantly increases the risk of sepsis mortality, with a 2.24-fold higher risk for sepsis as an underlying cause and a 2.11-fold higher risk when sepsis is a contributing factor, based on a study of 155,484 participants over an average of 11.6 years.
The risk associated with inadequate exercise is particularly pronounced in individuals with diabetes, showing a 4.78-fold increase in sepsis mortality risk, highlighting the importance of regular physical activity for this vulnerable group.
Inadequate exercise as a risk factor for sepsis mortality.Williams, PT.[2021]

References

ICU rehabilitation is associated with reduced long-term mortality from sepsis in patients with low skeletal muscle mass: a case control study. [2022]
Increased R-spondin 3 contributes to aerobic exercise-induced protection against renal vascular endothelial hyperpermeability and acute kidney injury. [2023]
Inadequate exercise as a risk factor for sepsis mortality. [2021]
Effects of Early Exercise Rehabilitation on Functional Recovery in Patients with Severe Sepsis. [2019]
Physical activity, muscle strength, and exercise capacity 3 months after severe sepsis and septic shock. [2022]
Aerobic Exercise Training and Inducible Inflammation: Results of a Randomized Controlled Trial in Healthy, Young Adults. [2023]
Exercise prescription: principles and current limitations. [2021]
Dynamic strength training intensity in cardiovascular rehabilitation: is it time to reconsider clinical practice? A systematic review. [2020]
Effects of resistance training on cytokines. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Effects of nonlinear resistance and aerobic interval training on cytokines and insulin resistance in sedentary men who are obese. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Low-intensity exercise in the acute phase of lipopolysaccharide-induced sepsis improves lipid metabolism and survival in mice by stimulating PGC-1α expression. [2018]
Moderate exercise-induced dynamics on key sepsis-associated signaling pathways in the liver. [2023]
13.United Statespubmed.ncbi.nlm.nih.gov
Exercise training attenuates septic responses in conscious rats. [2013]